Is the Mounjaro dose schedule the same as the Zepbound one?

The ladder is. Both begin at 2.5 mg once weekly and both rise in 2.5 mg increments after at least 4 weeks on the current dose, to the same 15 mg adult maximum, so 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg is one sequence and week 21 is the earliest anyone reaches the top on either product. What is not the same is what the labels tell you to do with it. Zepbound's first step is stated outright — "After 4 weeks, increase the dosage to 5 mg injected subcutaneously once weekly" — while Mounjaro's every step is conditional: "If additional glycemic control is needed, increase the dosage in 2.5 mg increments after at least 4 weeks on the current dose."

What is the maintenance dose of Mounjaro?

There isn't one, and that is a fact about the label rather than a gap in this page. The word "maintenance" does not appear in the Mounjaro Structured Product Label at all — zero occurrences in the full document, checked on 2026-09-20 — while it appears 21 times in Zepbound's, which has a whole section headed "Recommended Maintenance and Maximum Dosage" naming 5, 10, 15 mg for weight and 10 or 15 mg for sleep apnoea. Because Mounjaro escalates only if additional glycaemic control is needed, any rung is a legitimate stopping point for someone at target, including the 2.5 mg starting dose. Where you stop on Mounjaro is decided by your HbA1c and your prescriber, not by a labelled destination.

Can I stay on 2.5 mg?

On Mounjaro, the label gives no reason you cannot: it names no maintenance dosage, it escalates only if additional glycaemic control is needed, and a patient at target has met the condition for not escalating. On Zepbound the answer is the opposite and it is written out in a single sentence: "The 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage." That is the same milligram figure carrying two opposite labelled meanings, which is the most consequential thing on this page and the easiest one to get backwards from a chart.

Can children take either of these?

Only Mounjaro, and only for type 2 diabetes. Its section 8.4 states that the safety and effectiveness in patients aged 10 years and older have been established, supported by a 30-week randomised, double-blind, placebo-controlled trial with a 22-week open-label extension in 99 patients, and notes a higher incidence of vomiting, abdominal pain and hypoglycaemia than in adults. The paediatric maximum is 10 mg once weekly rather than 15 mg. Zepbound section 8.4 reads, in full: "The safety and effectiveness of ZEPBOUND have not been established in pediatric patients."

Is one of them easier on the stomach?

Nothing in these two labels establishes that, and the figures that look like they do are from different diseases. Mounjaro's table comes from 718 patients, mean duration of exposure 36.6 weeks with type 2 diabetes at a 5% reporting threshold; Zepbound's comes from 2,519 patients across two trials, up to 72 weeks plus 4 weeks off drug with obesity or overweight at 2%. At the same 15 mg dose, nausea reads 18% against 28%, but the placebo arms were 4% and 8%, which is half the apparent difference before the drug is involved. Both labels do make the same claim about time, in almost the same words: the reactions "occurred during dose escalation and decreased over time".

Is Zepbound cheaper than Mounjaro?

Marginally, in the same device, and substantially in a different one. In the CMS NADAC file dated 2026-09-16, a month of 15 mg in single-dose pens is $1,167 as Mounjaro and $1,139 as Zepbound — $6 per injection apart for an identical injection. Taking the same 15 mg from a four-dose Zepbound KwikPen instead brings the month to $728, and that gap is about the device rather than the brand. Our NADAC snapshot records no Mounjaro KwikPen NDC, so no equivalent multi-dose figure is given for Mounjaro rather than one being assumed. None of these is a price a patient can obtain: NADAC is what the pharmacy paid on invoice, not a cash price and not a copay.

Can I take Mounjaro and Zepbound together?

No, and only one of the two labels bothers to say so. Zepbound carries a Limitations of Use: "ZEPBOUND contains tirzepatide. Coadministration with other tirzepatide-containing products or with any glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended." The Mounjaro label has no Limitations of Use section and does not use the phrase "tirzepatide-containing" anywhere. Since the two products are the same molecule at the same strengths, taking both is simply taking a double dose of one drug, and the 15 mg weekly maximum applies to the total.

Head to head

Mounjaro vs Zepbound

Same molecule, same maker, same six strengths, same escalation. The word "maintenance" appears twenty-one times in one label and not once in the other — and that is the difference.

Reviewed September 2026

The short answer

These are the same drug in the same devices at the same doses. Tirzepatide, Eli Lilly, once weekly under the skin. Section 3 of the two labels is the same sentence with the brand name swapped, listing the same six strengths — 2.5 through 15 mg — in single-dose pens, single-dose vials, multi-dose vials and KwikPens.

The escalation is also the same. Both start at 2.5 mg once weekly and both rise in 2.5 mg steps "after at least 4 weeks on the current dose" to a 15 mg adult maximum, so 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg is one ladder, not two, and week 21 is the earliest anyone reaches the top on either.

What differs is where you are meant to stop, and the labels say it with a word rather than a number. "Maintenance" appears 21 times in the Zepbound label — it has a section headed "Recommended Maintenance and Maximum Dosage", it names 5, 10, 15 mg as maintenance dosages for weight, and it states that "The 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage." The word appears 0 times in the Mounjaro label. Not once.

That is not an oversight. Mounjaro escalates only "If additional glycemic control is needed", so a patient whose HbA1c is where it should be at 2.5 mg is at a labelled dose and has arrived. On Zepbound the same 2.5 mg is explicitly not a destination. Two opposite instructions built on one ladder, which is why a Zepbound titration chart should never be read against a Mounjaro prescription.

5 of 17 dimensions are materially the same. They are marked below rather than dressed up as differences.

Mounjaro

tirzepatide injection

Tirzepatide approved for type 2 diabetes in adults and children from age 10, and for cardiovascular risk reduction. NDA215866, Eli Lilly.

Dosing protocol →

Zepbound

tirzepatide injection

The same molecule approved for weight reduction and long-term maintenance, and for moderate-to-severe obstructive sleep apnoea with obesity. NDA217806, Eli Lilly.

Dosing protocol →

Side by side

Every row carries how well supported it is. A claim that only reflects common practice is labelled as such rather than presented as fact.

Dimension	Mounjaro	Zepbound	Basis
Active ingredientsame	Tirzepatide	Tirzepatide	labelIdentical molecule, identical manufacturer, identical once-weekly subcutaneous route, identical devices. Both labels describe it as "a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist".
FDA application	NDA215866, marketing category NDA	NDA217806, marketing category NDA	labelRead from the approval block of each Structured Product Label on 2026-09-20, not inferred from the brand name. Two genuine approvals for one molecule, held by the same company.
What it is approved to treat	Type 2 diabetes in adults and patients aged 10 and older; reduction of major adverse cardiovascular events in adults with type 2 diabetes at high risk	Weight reduction and long-term weight maintenance in obesity, or overweight with a weight-related comorbidity; moderate-to-severe obstructive sleep apnoea in adults with obesity	labelNo overlap. The Mounjaro label does not contain the word "obesity" once, and does not mention sleep apnoea at all. Prescribing Mounjaro for weight is off-label use of a brand whose identical molecule is on-label for weight under the other name.
Escalation laddersame	2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg	2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg	labelOne ladder, generated once from the rule both labels state and printed in both columns. Starting dosage 2.5 mg once weekly, increases "in 2.5 mg increments after at least 4 weeks on the current dose", adult maximum 15 mg once weekly. Week 21 is the earliest the top can be reached on either, and "at least 4 weeks" has no upper bound.
The word "maintenance"	Appears 0 times in the label	Appears 21 times in the label	labelCounted case-insensitively over the full Structured Product Label XML of each product on 2026-09-20. Zepbound has a numbered section called "Recommended Maintenance and Maximum Dosage". Mounjaro has no maintenance section, names no maintenance dosage, and never uses the word. This is the single row the rest of the page hangs on.
Is the starting dose a place you can stay?	Yes — nothing on the label says otherwise	No — the label rules it out in one sentence	labelZepbound 2.1, verbatim: "The 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage." Mounjaro carries no such sentence and escalates only "If additional glycemic control is needed", which makes every rung including 2.5 mg a legitimate destination for a patient who is at target. The same milligram figure, two opposite labelled meanings.
Named maintenance dosages	None named	5, 10, 15 mg for weight; 10 or 15 mg for obstructive sleep apnoea	labelZepbound gives two different maintenance lists for its two indications, and the sleep-apnoea list starts higher. Mounjaro gives none, so "what is the maintenance dose of Mounjaro" has no labelled answer and this page does not supply one from elsewhere.
What triggers the next step up	"If additional glycemic control is needed"	A calendar, then tolerability	labelMounjaro 2.1, verbatim: "If additional glycemic control is needed, increase the dosage in 2.5 mg increments after at least 4 weeks on the current dose." Zepbound 2.1: "After 4 weeks, increase the dosage to 5 mg injected subcutaneously once weekly. The dosage may be increased in 2.5 mg increments, after at least 4 weeks on the current dose." One label makes the first step up automatic and the rest permissive; the other makes every step conditional on a laboratory result.
Maximum dosage	15 mg weekly in adults; 10 mg in patients aged 10 and older	15 mg weekly, all indications	labelThe adult ceiling is the same. Mounjaro carries a second, lower one that Zepbound has no equivalent for, because Zepbound has no paediatric patients: the paediatric ladder tops out at 10 mg, reachable no earlier than week 13.
Paediatric use	Established from age 10 in type 2 diabetes	Not established at any age	labelMounjaro 8.4 states the safety and effectiveness in patients aged 10 and older "have been established", supported by a 30-week randomised placebo-controlled trial with a 22-week open-label extension in 99 patients, and notes a higher incidence of vomiting, abdominal pain and hypoglycaemia than in adults. Zepbound 8.4, verbatim: "The safety and effectiveness of ZEPBOUND have not been established in pediatric patients."
Taking both at once	The label says nothing	Limitations of Use warns against it	labelZepbound, verbatim: "ZEPBOUND contains tirzepatide. Coadministration with other tirzepatide-containing products or with any glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended." The Mounjaro label has no Limitations of Use section and does not contain the phrase "tirzepatide-containing" at all. Only one half of the pair warns you about the other half.
Label says gut effects decrease over timesame	Yes — "and decreased over time"	Yes — "and decreased over time"	labelBoth, near-verbatim. Mounjaro: "The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation and decreased over time." Zepbound: "The majority of nausea, vomiting, and/or diarrhea events occurred during dose escalation and decreased over time." Those four words are what separates the tirzepatide labels from every semaglutide label, and they are on both of these.
When people stop because of it	Not stated	Stated	labelZepbound 6.1, verbatim: "The majority of patients who discontinued ZEPBOUND due to adverse reactions did so during the first few months of treatment due to gastrointestinal adverse reactions." Mounjaro's section 6.1 makes no equivalent statement, so no timing is given in its column rather than the Zepbound sentence being borrowed for it.
Nausea in each label's own trial pool	18% at 15 mg vs 4% placebo (+14 pts)	28% at 15 mg vs 8% placebo (+20 pts)	labelTwo different trial programmes in two different diseases, so these are not a head-to-head even though the molecule and the dose are identical. Mounjaro's Table 1 pools 718 patients, mean duration of exposure 36.6 weeks with type 2 diabetes at a 5% threshold; Zepbound's pools 2,519 patients across two trials, up to 72 weeks plus 4 weeks off drug with obesity or overweight at 2%. Any GI reaction, excess over placebo: +23.2 pts against +26 pts.
Missed dose and changing your daysame	Within 4 days (96 hours); at least 3 days (72 hours) between doses	Within 4 days (96 hours); at least 3 days (72 hours) between doses	labelIdentical instructions, identical parenthetical hour figures, in the same order. One of several places where the two documents are the same document.
Boxed warningsame	Risk of thyroid C-cell tumours	Risk of thyroid C-cell tumours	labelThe same rodent finding, the same uncertainty about human relevance, and the same contraindication in personal or family history of medullary thyroid carcinoma or MEN 2, with only the brand name differing.
What a pharmacy paid, per month	$1,167 — 15 mg single-dose pens	$1,139 single-dose pens, $728 KwikPen — 15 mg	literatureCMS NADAC, file dated 2026-09-16: invoice cost to a retail pharmacy, not a cash price and not a copay. In the same device at the same dose the two brands are $6 apart per injection, which is the price of the name. The Zepbound KwikPen figure is a different device, not a different drug — and the snapshot carries no Mounjaro KwikPen NDC, so no equivalent device saving is computed for Mounjaro rather than one being assumed from its sibling.

label: Stated on the FDA label
guideline: Clinical practice guideline
literature: Published literature
practice: Common practice, not documented

Which one

Choose Mounjaro if

You have type 2 diabetes. That is the Mounjaro indication, and it is the reason the label gates every dose increase on glycaemic control rather than on the calendar.
The patient is 10 to 17 with type 2 diabetes. Mounjaro is established in that age group with its own 10 mg ceiling; Zepbound is not established in anyone under 18.
You are at target on a low dose and want to stay there. Mounjaro names no maintenance dosage and no minimum, so 2.5 mg or 5 mg is a labelled place to stop if your numbers are where they should be.
Cardiovascular risk reduction in type 2 diabetes is part of why it was prescribed — that indication is on the Mounjaro label and on no Zepbound label.

Choose Zepbound if

Weight reduction is the goal. It is a labelled Zepbound indication and appears nowhere on the Mounjaro label, which never uses the word "obesity".
You have moderate-to-severe obstructive sleep apnoea with obesity. Zepbound is the only tirzepatide product approved for it, at a maintenance dosage of 10 or 15 mg.
You want the label that tells you where the ladder ends. Zepbound names its maintenance dosages, rules 2.5 mg out as a destination, and says when the people who quit tend to quit.
Acquisition cost is being paid close to invoice and the KwikPen is available — it is the only device in this pair for which a large per-injection saving is recorded, and the recorded saving belongs to Zepbound.

Nothing in a comparison of these two is a comparison of drugs. It is a comparison of two documents describing one molecule, and the document decides your indication, your paediatric eligibility, whether your starting dose counts as a destination, and what your plan is being asked to cover. The trap worth naming is the titration chart: the ladders are genuinely identical, which is exactly why a Zepbound chart looks like it applies to a Mounjaro prescription. It does not. One label says 2.5 mg is not a maintenance dosage and the other has no concept of a maintenance dosage at all.

Frequently asked questions

Are Mounjaro and Zepbound the same thing?: Same molecule, same manufacturer, same devices, same strengths — and two different approvals. Mounjaro is NDA215866, for type 2 diabetes in adults and patients aged 10 and older and for cardiovascular risk reduction; Zepbound is NDA217806, for weight reduction and long-term weight maintenance and for moderate-to-severe obstructive sleep apnoea with obesity. Section 3 of both labels is the same sentence, listing 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg in pre-filled single-dose pens, single-dose vials, multi-dose vials and single-patient-use KwikPens. If you held two cartons with the brand names covered, nothing in the dosage forms section would tell them apart.
Is the Mounjaro dose schedule the same as the Zepbound one?: The ladder is. Both begin at 2.5 mg once weekly and both rise in 2.5 mg increments after at least 4 weeks on the current dose, to the same 15 mg adult maximum, so 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg is one sequence and week 21 is the earliest anyone reaches the top on either product. What is not the same is what the labels tell you to do with it. Zepbound's first step is stated outright — "After 4 weeks, increase the dosage to 5 mg injected subcutaneously once weekly" — while Mounjaro's every step is conditional: "If additional glycemic control is needed, increase the dosage in 2.5 mg increments after at least 4 weeks on the current dose."
What is the maintenance dose of Mounjaro?: There isn't one, and that is a fact about the label rather than a gap in this page. The word "maintenance" does not appear in the Mounjaro Structured Product Label at all — zero occurrences in the full document, checked on 2026-09-20 — while it appears 21 times in Zepbound's, which has a whole section headed "Recommended Maintenance and Maximum Dosage" naming 5, 10, 15 mg for weight and 10 or 15 mg for sleep apnoea. Because Mounjaro escalates only if additional glycaemic control is needed, any rung is a legitimate stopping point for someone at target, including the 2.5 mg starting dose. Where you stop on Mounjaro is decided by your HbA1c and your prescriber, not by a labelled destination.
Can I stay on 2.5 mg?: On Mounjaro, the label gives no reason you cannot: it names no maintenance dosage, it escalates only if additional glycaemic control is needed, and a patient at target has met the condition for not escalating. On Zepbound the answer is the opposite and it is written out in a single sentence: "The 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage." That is the same milligram figure carrying two opposite labelled meanings, which is the most consequential thing on this page and the easiest one to get backwards from a chart.
Can children take either of these?: Only Mounjaro, and only for type 2 diabetes. Its section 8.4 states that the safety and effectiveness in patients aged 10 years and older have been established, supported by a 30-week randomised, double-blind, placebo-controlled trial with a 22-week open-label extension in 99 patients, and notes a higher incidence of vomiting, abdominal pain and hypoglycaemia than in adults. The paediatric maximum is 10 mg once weekly rather than 15 mg. Zepbound section 8.4 reads, in full: "The safety and effectiveness of ZEPBOUND have not been established in pediatric patients."
Is one of them easier on the stomach?: Nothing in these two labels establishes that, and the figures that look like they do are from different diseases. Mounjaro's table comes from 718 patients, mean duration of exposure 36.6 weeks with type 2 diabetes at a 5% reporting threshold; Zepbound's comes from 2,519 patients across two trials, up to 72 weeks plus 4 weeks off drug with obesity or overweight at 2%. At the same 15 mg dose, nausea reads 18% against 28%, but the placebo arms were 4% and 8%, which is half the apparent difference before the drug is involved. Both labels do make the same claim about time, in almost the same words: the reactions "occurred during dose escalation and decreased over time".
Is Zepbound cheaper than Mounjaro?: Marginally, in the same device, and substantially in a different one. In the CMS NADAC file dated 2026-09-16, a month of 15 mg in single-dose pens is $1,167 as Mounjaro and $1,139 as Zepbound — $6 per injection apart for an identical injection. Taking the same 15 mg from a four-dose Zepbound KwikPen instead brings the month to $728, and that gap is about the device rather than the brand. Our NADAC snapshot records no Mounjaro KwikPen NDC, so no equivalent multi-dose figure is given for Mounjaro rather than one being assumed. None of these is a price a patient can obtain: NADAC is what the pharmacy paid on invoice, not a cash price and not a copay.
Can I take Mounjaro and Zepbound together?: No, and only one of the two labels bothers to say so. Zepbound carries a Limitations of Use: "ZEPBOUND contains tirzepatide. Coadministration with other tirzepatide-containing products or with any glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended." The Mounjaro label has no Limitations of Use section and does not use the phrase "tirzepatide-containing" anywhere. Since the two products are the same molecule at the same strengths, taking both is simply taking a double dose of one drug, and the 15 mg weekly maximum applies to the total.

Sources

Next steps

Compare online weight-loss providersWhich platforms prescribe branded Zepbound, which write Mounjaro off-label, and what each charges.Medical weight loss, start to finishEligibility, the first six months, monitoring, and what happens if you stop.

Other comparisons

Educational reference, not medical advice. Which medication suits you is a decision for your prescriber.